Brain Tumor Therapeutics - Global Strategic Business Report

The global market for Brain Tumor Therapeutics is estimated at US$1.9 Billion in 2023 and is projected to reach US$4.2 Billion by 2030, growing at a CAGR of 10.5% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Key Insights:

Market Growth: Understand the significant growth trajectory of the MRI segment, which is expected to reach US$2.2 Billion by 2030 with a CAGR of 11.8%. The CT Scan segment is also set to grow at 10.5% CAGR over the next 8 years.
Regional Analysis: Gain insights into the U.S. market, estimated at $573.4 Million in 2023, and China, forecasted to grow at an impressive 9.9% CAGR to reach $715 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

Detailed Market Analysis: Access a thorough analysis of the Global Brain Tumor Therapeutics Market, covering all major geographic regions and market segments.
Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Brain Tumor Therapeutics Market.
Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

How is the Global Brain Tumor Therapeutics Market expected to evolve by 2030?
What are the main drivers and restraints affecting the market?
Which market segments will grow the most over the forecast period?
How will market shares for different regions and segments change by 2030?
Who are the leading players in the market, and what are their prospects?

Report Features:

Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
Company Profiles: Coverage of major players such as AstraZeneca PLC, Bristol-Myers Squibb Company, DelMar Pharmaceuticals, Inc., and more.
Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 13 Featured):

AstraZeneca PLC
Bristol-Myers Squibb Company
DelMar Pharmaceuticals, Inc.
Eisai Co., Ltd.
Emcure Pharmaceuticals Pvt., Ltd.
F. Hoffmann-La Roche AG
Fresenius Kabi Oncology Ltd.
ImmunoCellular Therapeutics Ltd.
iTeos Therapeutics SA
Kazia Therapeutics Ltd.
Merck & Co., Inc.
Moleculin Biotech, Inc.
Navinta LLC
NextSource Biotechnology, LLC
Northwest Biotherapeutics, Inc.
Novartis International AG
NovoCure Ltd. (Channel Islands)
Tocagen, Inc.
United Technologies Corporation (UTC)

MarketGlass Platform

Our reports are enhanced by the MarketGlass platform, which brings together industry experts and influencers to provide high-quality, accurate insights. This unique platform allows us to gather comprehensive data and market perspectives, ensuring you receive the most reliable and detailed analysis available.

I. METHODOLOGYII. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights
World Market Trajectories
Brain Tumor Therapeutics - Global Key Competitors Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
Global Economic Update

2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

Table 1: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 2: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 3: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 4: World Recent Past, Current & Future Analysis for Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 5: World Historic Review for Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 6: World 16-Year Perspective for Gene Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 7: World Brain Tumor Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
Table 8: World Recent Past, Current & Future Analysis for Brain Tumor Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 9: World Historic Review for Brain Tumor Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 10: World 16-Year Perspective for Brain Tumor Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
Table 11: World Recent Past, Current & Future Analysis for MRI by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 12: World Historic Review for MRI by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 13: World 16-Year Perspective for MRI by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 14: World Recent Past, Current & Future Analysis for CT Scan by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 15: World Historic Review for CT Scan by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 16: World 16-Year Perspective for CT Scan by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 17: World Recent Past, Current & Future Analysis for Lumbar Puncture by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 18: World Historic Review for Lumbar Puncture by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 19: World 16-Year Perspective for Lumbar Puncture by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 20: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 21: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 22: World 16-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 23: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 24: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 25: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 26: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 27: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 28: World 16-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

UNITED STATES

Brain Tumor Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
Table 29: USA Recent Past, Current & Future Analysis for Brain Tumor Therapeutics by Therapy - Chemotherapy, Gene Therapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 30: USA Historic Review for Brain Tumor Therapeutics by Therapy - Chemotherapy, Gene Therapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 31: USA 16-Year Perspective for Brain Tumor Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Gene Therapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
Table 32: USA Recent Past, Current & Future Analysis for Brain Tumor Therapeutics by Type - MRI, CT Scan, Lumbar Puncture and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 33: USA Historic Review for Brain Tumor Therapeutics by Type - MRI, CT Scan, Lumbar Puncture and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 34: USA 16-Year Perspective for Brain Tumor Therapeutics by Type - Percentage Breakdown of Value Sales for MRI, CT Scan, Lumbar Puncture and Other Types for the Years 2014, 2024 & 2030

CANADA

Table 35: Canada Recent Past, Current & Future Analysis for Brain Tumor Therapeutics by Therapy - Chemotherapy, Gene Therapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 36: Canada Historic Review for Brain Tumor Therapeutics by Therapy - Chemotherapy, Gene Therapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 37: Canada 16-Year Perspective for Brain Tumor Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Gene Therapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
Table 38: Canada Recent Past, Current & Future Analysis for Brain Tumor Therapeutics by Type - MRI, CT Scan, Lumbar Puncture and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 39: Canada Historic Review for Brain Tumor Therapeutics by Type - MRI, CT Scan, Lumbar Puncture and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 40: Canada 16-Year Perspective for Brain Tumor Therapeutics by Type - Percentage Breakdown of Value Sales for MRI, CT Scan, Lumbar Puncture and Other Types for the Years 2014, 2024 & 2030

JAPAN

Brain Tumor Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
Table 41: Japan Recent Past, Current & Future Analysis for Brain Tumor Therapeutics by Therapy - Chemotherapy, Gene Therapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 42: Japan Historic Review for Brain Tumor Therapeutics by Therapy - Chemotherapy, Gene Therapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 43: Japan 16-Year Perspective for Brain Tumor Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Gene Therapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
Table 44: Japan Recent Past, Current & Future Analysis for Brain Tumor Therapeutics by Type - MRI, CT Scan, Lumbar Puncture and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 45: Japan Historic Review for Brain Tumor Therapeutics by Type - MRI, CT Scan, Lumbar Puncture and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 46: Japan 16-Year Perspective for Brain Tumor Therapeutics by Type - Percentage Breakdown of Value Sales for MRI, CT Scan, Lumbar Puncture and Other Types for the Years 2014, 2024 & 2030

CHINA

Brain Tumor Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
Table 47: China Recent Past, Current & Future Analysis for Brain Tumor Therapeutics by Therapy - Chemotherapy, Gene Therapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 48: China Historic Review for Brain Tumor Therapeutics by Therapy - Chemotherapy, Gene Therapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 49: China 16-Year Perspective for Brain Tumor Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Gene Therapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
Table 50: China Recent Past, Current & Future Analysis for Brain Tumor Therapeutics by Type - MRI, CT Scan, Lumbar Puncture and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 51: China Historic Review for Brain Tumor Therapeutics by Type - MRI, CT Scan, Lumbar Puncture and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 52: China 16-Year Perspective for Brain Tumor Therapeutics by Type - Percentage Breakdown of Value Sales for MRI, CT Scan, Lumbar Puncture and Other Types for the Years 2014, 2024 & 2030

EUROPE

Brain Tumor Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
Table 53: Europe Recent Past, Current & Future Analysis for Brain Tumor Therapeutics by Therapy - Chemotherapy, Gene Therapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 54: Europe Historic Review for Brain Tumor Therapeutics by Therapy - Chemotherapy, Gene Therapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 55: Europe 16-Year Perspective for Brain Tumor Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Gene Therapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
Table 56: Europe Recent Past, Current & Future Analysis for Brain Tumor Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 57: Europe Historic Review for Brain Tumor Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 58: Europe 16-Year Perspective for Brain Tumor Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
Table 59: Europe Recent Past, Current & Future Analysis for Brain Tumor Therapeutics by Type - MRI, CT Scan, Lumbar Puncture and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 60: Europe Historic Review for Brain Tumor Therapeutics by Type - MRI, CT Scan, Lumbar Puncture and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 61: Europe 16-Year Perspective for Brain Tumor Therapeutics by Type - Percentage Breakdown of Value Sales for MRI, CT Scan, Lumbar Puncture and Other Types for the Years 2014, 2024 & 2030

FRANCE

Brain Tumor Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
Table 62: France Recent Past, Current & Future Analysis for Brain Tumor Therapeutics by Therapy - Chemotherapy, Gene Therapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 63: France Historic Review for Brain Tumor Therapeutics by Therapy - Chemotherapy, Gene Therapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 64: France 16-Year Perspective for Brain Tumor Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Gene Therapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
Table 65: France Recent Past, Current & Future Analysis for Brain Tumor Therapeutics by Type - MRI, CT Scan, Lumbar Puncture and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 66: France Historic Review for Brain Tumor Therapeutics by Type - MRI, CT Scan, Lumbar Puncture and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 67: France 16-Year Perspective for Brain Tumor Therapeutics by Type - Percentage Breakdown of Value Sales for MRI, CT Scan, Lumbar Puncture and Other Types for the Years 2014, 2024 & 2030

GERMANY

Brain Tumor Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
Table 68: Germany Recent Past, Current & Future Analysis for Brain Tumor Therapeutics by Therapy - Chemotherapy, Gene Therapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 69: Germany Historic Review for Brain Tumor Therapeutics by Therapy - Chemotherapy, Gene Therapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 70: Germany 16-Year Perspective for Brain Tumor Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Gene Therapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
Table 71: Germany Recent Past, Current & Future Analysis for Brain Tumor Therapeutics by Type - MRI, CT Scan, Lumbar Puncture and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 72: Germany Historic Review for Brain Tumor Therapeutics by Type - MRI, CT Scan, Lumbar Puncture and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 73: Germany 16-Year Perspective for Brain Tumor Therapeutics by Type - Percentage Breakdown of Value Sales for MRI, CT Scan, Lumbar Puncture and Other Types for the Years 2014, 2024 & 2030

ITALY

Table 74: Italy Recent Past, Current & Future Analysis for Brain Tumor Therapeutics by Therapy - Chemotherapy, Gene Therapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 75: Italy Historic Review for Brain Tumor Therapeutics by Therapy - Chemotherapy, Gene Therapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 76: Italy 16-Year Perspective for Brain Tumor Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Gene Therapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
Table 77: Italy Recent Past, Current & Future Analysis for Brain Tumor Therapeutics by Type - MRI, CT Scan, Lumbar Puncture and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 78: Italy Historic Review for Brain Tumor Therapeutics by Type - MRI, CT Scan, Lumbar Puncture and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 79: Italy 16-Year Perspective for Brain Tumor Therapeutics by Type - Percentage Breakdown of Value Sales for MRI, CT Scan, Lumbar Puncture and Other Types for the Years 2014, 2024 & 2030

UNITED KINGDOM

Brain Tumor Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
Table 80: UK Recent Past, Current & Future Analysis for Brain Tumor Therapeutics by Therapy - Chemotherapy, Gene Therapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 81: UK Historic Review for Brain Tumor Therapeutics by Therapy - Chemotherapy, Gene Therapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 82: UK 16-Year Perspective for Brain Tumor Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Gene Therapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
Table 83: UK Recent Past, Current & Future Analysis for Brain Tumor Therapeutics by Type - MRI, CT Scan, Lumbar Puncture and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 84: UK Historic Review for Brain Tumor Therapeutics by Type - MRI, CT Scan, Lumbar Puncture and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 85: UK 16-Year Perspective for Brain Tumor Therapeutics by Type - Percentage Breakdown of Value Sales for MRI, CT Scan, Lumbar Puncture and Other Types for the Years 2014, 2024 & 2030

REST OF EUROPE

Table 86: Rest of Europe Recent Past, Current & Future Analysis for Brain Tumor Therapeutics by Therapy - Chemotherapy, Gene Therapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 87: Rest of Europe Historic Review for Brain Tumor Therapeutics by Therapy - Chemotherapy, Gene Therapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 88: Rest of Europe 16-Year Perspective for Brain Tumor Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Gene Therapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
Table 89: Rest of Europe Recent Past, Current & Future Analysis for Brain Tumor Therapeutics by Type - MRI, CT Scan, Lumbar Puncture and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 90: Rest of Europe Historic Review for Brain Tumor Therapeutics by Type - MRI, CT Scan, Lumbar Puncture and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 91: Rest of Europe 16-Year Perspective for Brain Tumor Therapeutics by Type - Percentage Breakdown of Value Sales for MRI, CT Scan, Lumbar Puncture and Other Types for the Years 2014, 2024 & 2030

ASIA-PACIFIC

Brain Tumor Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
Table 92: Asia-Pacific Recent Past, Current & Future Analysis for Brain Tumor Therapeutics by Therapy - Chemotherapy, Gene Therapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 93: Asia-Pacific Historic Review for Brain Tumor Therapeutics by Therapy - Chemotherapy, Gene Therapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 94: Asia-Pacific 16-Year Perspective for Brain Tumor Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Gene Therapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
Table 95: Asia-Pacific Recent Past, Current & Future Analysis for Brain Tumor Therapeutics by Type - MRI, CT Scan, Lumbar Puncture and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 96: Asia-Pacific Historic Review for Brain Tumor Therapeutics by Type - MRI, CT Scan, Lumbar Puncture and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 97: Asia-Pacific 16-Year Perspective for Brain Tumor Therapeutics by Type - Percentage Breakdown of Value Sales for MRI, CT Scan, Lumbar Puncture and Other Types for the Years 2014, 2024 & 2030

REST OF WORLD

Table 98: Rest of World Recent Past, Current & Future Analysis for Brain Tumor Therapeutics by Therapy - Chemotherapy, Gene Therapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 99: Rest of World Historic Review for Brain Tumor Therapeutics by Therapy - Chemotherapy, Gene Therapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 100: Rest of World 16-Year Perspective for Brain Tumor Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Gene Therapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
Table 101: Rest of World Recent Past, Current & Future Analysis for Brain Tumor Therapeutics by Type - MRI, CT Scan, Lumbar Puncture and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 102: Rest of World Historic Review for Brain Tumor Therapeutics by Type - MRI, CT Scan, Lumbar Puncture and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 103: Rest of World 16-Year Perspective for Brain Tumor Therapeutics by Type - Percentage Breakdown of Value Sales for MRI, CT Scan, Lumbar Puncture and Other Types for the Years 2014, 2024 & 2030

IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

AstraZeneca PLC
Bristol-Myers Squibb Company
DelMar Pharmaceuticals, Inc.
Eisai Co., Ltd.
Emcure Pharmaceuticals Pvt., Ltd.
F. Hoffmann-La Roche AG
Fresenius Kabi Oncology Ltd.
ImmunoCellular Therapeutics Ltd.
iTeos Therapeutics SA
Kazia Therapeutics Ltd.
Merck & Co., Inc.
Moleculin Biotech, Inc.
Navinta LLC
NextSource Biotechnology, LLC
Northwest Biotherapeutics, Inc.
Novartis International AG
NovoCure Ltd. (Channel Islands)
Tocagen, Inc.
United Technologies Corporation (UTC)

Table Information

Report Attribute	Details
No. of Pages	182
Published	October 2025
Forecast Period	2023 - 2030
Estimated Market Value ( USD ) in 2023	$ 1.9 Billion
Forecasted Market Value ( USD ) by 2030	$ 4.2 Billion
Compound Annual Growth Rate	10.5%
Regions Covered	Global

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€4405EUR$4,950USD£3,877GBP
1 - 10 USER LICENSE PDF	The product is a PDF.	This is a 1-10 user license, allowing up to ten users have access to the product.	€8369EUR$9,405USD£7,367GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€13214EUR$14,850USD£11,632GBP

Key Insights:

Why You Should Buy This Report:

Key Questions Answered:

Report Features:

Select Competitors (Total 13 Featured):

MarketGlass Platform

Table of Contents

Companies Mentioned (Partial List)

Table Information

Related Topics

Related Reports

Brain Tumor Therapeutics Market - Global Forecast 2025-2032

2025 Global Forecast for Brain Tumor Therapeutics Market (2026-2031 Outlook)-High Tech Outlook Report

Brain Tumor Diagnosis and Treatment - Global Strategic Business Report

Brain Tumor Diagnosis and Therapeutics Market Size, Share & Trends Analysis Report by Type (Primary, Secondary), Product, Diagnosis (MRI, CT, PET-CT), Therapeutics, End Use, and Region with Growth Forecasts, 2025-2030

Glioblastoma Multiforme Global Market Report 2025